-- Range Resources (RRC) reported Q1 adjusted earnings Tuesday of $1.52 per diluted share, up from $0.96 a year earlier.
Analysts polled by FactSet expected $1.30.
Revenue in the three months ended March 31 rose to $1.03 billion from $690.6 million a year earlier.
Analysts surveyed by FactSet expected $925.2 million.
Range Resources shares rose 1.3% in after-hours trading.
Corporate Travel Management (ASX:CTD) now expects to reverse up to 118 million pounds sterling of revenue from fiscal year 2025 and prior years' results, up from a previously flagged amount of 77.6 million pounds sterling, according to a Wednesday filing with the Australian bourse.The development comes after the company hired KPMG to perform a forensic accounting review for certain years, with KPMG identifying areas of concern regarding the recognition of the UK group's concluded customer contracts and other revenue.The company said revenue of up to about 10 million pounds sterling may need to be reversed in the fiscal first-half results, depending on the outcome of commercial discussions with certain customers. The review confirmed that certain customers were charged above the contractual entitlement.Corporate Travel Management has made "significant changes" within its UK business, especially across financial controls and operational processes, it said, adding that the review has not identified any issues in other regions.The company aims to release audited fiscal year 2025 and reviewed fiscal first-half 2026 financial statements in the second quarter of the year.
Northern Star Resources (ASX:NST) said that the total gold sold for the March quarter was 380,807 ounces at an all-in sustaining cost (AISC) of AU$2,709 per ounce, according to a Wednesday Australian bourse filing.Total gold sold was 385,441 ounces at an AISC of AU$2,246 per ounce in the March 2025 quarter, an earlier filing showed.The company expects gold sales in fiscal 2026 to exceed 1.5 million ounces, with AISC projected between AU$2,600 and AU$2,800 per ounce.The company reported net cash of AU$320 million after paying a AU$347 million cash dividend, with total cash and bullion holdings amounting to AU$1.18 billion as of March 31.Northern Star Resources' shares shed around 2% in recent Wednesday trade.
Japanese pharmaceutical firm Eisai (TYO:4523) and U.S.-based Merck's experimental combination therapies failed to meet the dual primary endpoints of progression-free survival and overall survival in a Phase 3 trial.The trial was evaluating first-line treatment for advanced clear cell renal cell carcinoma, a form of kidney cancer that accounts for approximately 80% of all cases, according to a joint statement on Tuesday.The LITESPARK-012 study tested two regimens: Keytruda plus Lenvima plus Welireg, and MK-1308A (a co-formulation of Keytruda with an investigational antibody) plus Lenvima, against the established combination of Keytruda and Lenvima in 1,688 patients.An interim analysis revealed that neither experimental combination met the study's two primary goals of improving overall survival and progression-free survival compared with the standard treatment.